Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering ...

Older members of the 4x4 fraternity will remember the so called “capstan winches”; well, they're back. which were fitted vehicle wheel hubs. They allowed self-recovery as well as vehicle/vehicle ...

Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...

NORTH CHICAGO - AbbVie (NYSE:ABBV), a $365 billion market cap biotechnology giant with over $58 billion in annual revenue, announced Tuesday it has completed its acquisition of Capstan Therapeutics, ...

AbbVie will pay US$2.1 billion to acquire Capstan Therapeutics and its in vivo CAR T technology, which uses mRNA-loaded lipid nanoparticles (LNPs) to reprogramme immune cells. Capstan’s lead asset is ...

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up ...

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...

AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., drugmaker's planned acquisition includes CPTX2309, which is currently in ...

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is ...